BR112013005069A2 - Uso de uma preparação para a fabricação de um produto para a prevenção ou o tratamento de ansiedade ou depressão - Google Patents

Uso de uma preparação para a fabricação de um produto para a prevenção ou o tratamento de ansiedade ou depressão Download PDF

Info

Publication number
BR112013005069A2
BR112013005069A2 BR112013005069-1A BR112013005069A BR112013005069A2 BR 112013005069 A2 BR112013005069 A2 BR 112013005069A2 BR 112013005069 A BR112013005069 A BR 112013005069A BR 112013005069 A2 BR112013005069 A2 BR 112013005069A2
Authority
BR
Brazil
Prior art keywords
preparation
anxiety
depression
prevention
treatment
Prior art date
Application number
BR112013005069-1A
Other languages
English (en)
Inventor
Homberg Judith
Johanne Kiliaan Amanda
Maria Broersen Ladislaus
Original Assignee
N.V. Nutricia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by N.V. Nutricia filed Critical N.V. Nutricia
Publication of BR112013005069A2 publication Critical patent/BR112013005069A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pediatric Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

uso de uma preparação para a fabricação de um produto para a prevenção ou o tratamento de ansiedade ou depressão a presente invenção refere-se à utilização de uma preparação, especialmente uma preparação nutritiva, para a prevenção ou o tratamento da ansiedade em um indivíduo, especialmente em um indivíduo deprimido, e da depressão. mais especificamente, a presente invenção refere-se à utilização de uma preparação, especialmente uma preparação nutritiva, para a prevenção ou o tratamento de ansiedade ou depressão em um indivíduo que é não responsivo à medicação ssri. além disso, a invenção refere-se à utilização de uma preparação, especialmente uma preparação nutricional, para a regulação da neurogênese. a preparação compreende os seguintes componentes: a) pelo menos um ácido graxo poliinsaturado omega-3 (pufa) ; b) pelo menos dois fosfolipídeos selecionados do grupo que consiste em fosfatidilserina, fosfatidilinositol, fosfatidilcolina e fosfatidiletanolamina ou qualquer mistura deles; e c) um ou mais compostos que são um fator no metabolismo da serotonina, selecionados do grupo de vitaminas b e triptofano.
BR112013005069-1A 2010-09-03 2010-09-03 Uso de uma preparação para a fabricação de um produto para a prevenção ou o tratamento de ansiedade ou depressão BR112013005069A2 (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/NL2010/050558 WO2012030208A1 (en) 2010-09-03 2010-09-03 Method and preparation for the treatment or prevention of anxiety or neurogenesis

Publications (1)

Publication Number Publication Date
BR112013005069A2 true BR112013005069A2 (pt) 2020-06-16

Family

ID=43983780

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013005069-1A BR112013005069A2 (pt) 2010-09-03 2010-09-03 Uso de uma preparação para a fabricação de um produto para a prevenção ou o tratamento de ansiedade ou depressão

Country Status (6)

Country Link
US (1) US20130230503A1 (pt)
EP (1) EP2611313A1 (pt)
CN (1) CN103200830A (pt)
BR (1) BR112013005069A2 (pt)
RU (1) RU2606841C2 (pt)
WO (1) WO2012030208A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6104242B2 (ja) 2011-07-12 2017-03-29 フードチェク・システムズ・インコーポレイテッドＦｏｏｄｃｈｅｋ Ｓｙｓｔｅｍｓ， Ｉｎｃ． サルモネラおよび大腸菌を培養するための培養培地、方法、ならびにサルモネラおよび大腸菌を検出するための方法
CN104435100B (zh) * 2014-12-29 2016-01-06 青岛大学 一种抗抑郁组合物
CN107708446A (zh) 2015-06-22 2018-02-16 雀巢产品技术援助有限公司 用于增强动物体内神经形成的组合物和方法
MX2018001225A (es) 2015-07-29 2018-05-22 Abbott Lab Productos nutricionales con biodisponibilidad y solubilidad lipofilica mejoradas en una forma facil de mezclar.
DK3337487T3 (da) * 2015-08-17 2021-05-25 St Ip Holding Ag Honokiol- og magnololformuleringer med øget stabilitet og forbedret optagelse og fremgangsmåder til anvendelse deraf
CN106690309B (zh) * 2016-12-27 2020-05-05 天津市康世生物技术有限公司 一种具有缓解焦虑、改善睡眠作用的组合物及其应用
CN109198642A (zh) * 2018-09-19 2019-01-15 江苏金惠甫山软件科技有限公司 缓解心理压力的组合物及其口服制剂
US20240173295A1 (en) * 2021-03-25 2024-05-30 Brain Luxury Inc. A stable, emulsion-forming liquid composition comprising amino acids
CN113892521A (zh) * 2021-10-22 2022-01-07 广州博罗霍生物科技有限公司 辅助缓解焦虑和抑郁症状的含宝乐果粉的复合粉及其制备方法
CN116138457A (zh) * 2022-12-14 2023-05-23 温州医科大学 一种具有缓解抑郁样症状作用的复合营养组合物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2824362A1 (de) * 1978-06-01 1979-12-13 Josef Dipl Chem Dr Rer N Klosa Pharmazeutisches praeparat mit l-tryptophan
US7208180B2 (en) * 2000-05-08 2007-04-24 N.V. Nutricia Method and preparation for the preventing and/or treating vascular disorders and secondary disorders associated therewith
US20050002992A1 (en) * 2003-06-17 2005-01-06 Mccleary Edward Larry Foods, beverages, condiments, spices and salad dressings with specialized supplements
US6964969B2 (en) * 2001-04-19 2005-11-15 Mccleary Edward Larry Composition and method for treating impaired or deteriorating neurological function
AU2002320251A1 (en) * 2001-07-05 2003-01-21 Vital Basics, Inc. Compositions for improving mental performance
NL1019368C2 (nl) * 2001-11-14 2003-05-20 Nutricia Nv Preparaat voor het verbeteren van receptorwerking.
ITMI20030036A1 (it) * 2003-01-13 2004-07-14 Hunza Di Pistolesi Elvira & C S A S Preparazioni farmacologiche o dietetiche costituite da
US8075910B2 (en) * 2004-05-20 2011-12-13 Pbm Pharmaceuticals, Inc. Oral compositions comprising edible oils and vitamins and/or minerals and methods for making oral compositions
DK1800675T3 (da) * 2005-12-23 2011-09-05 Nutricia Nv Sammensætninger omfattende polyumættede fedtsyrer, proteiner og mangan og/eller molybdæn og nucleosider/nucleotider til behandling af demens
DE202007000949U1 (de) * 2007-01-23 2007-04-12 Vogel Lukas Nahrungsergänzungsmittel, bilanzierte Diät oder Arzneimittel für besonders medizinische Zwecke
US20090110674A1 (en) * 2007-10-24 2009-04-30 Loizou Nicos C Health supplement

Also Published As

Publication number Publication date
RU2606841C2 (ru) 2017-01-10
RU2013114826A (ru) 2014-10-10
CN103200830A (zh) 2013-07-10
US20130230503A1 (en) 2013-09-05
WO2012030208A1 (en) 2012-03-08
EP2611313A1 (en) 2013-07-10

Similar Documents

Publication Publication Date Title
BR112013005069A2 (pt) Uso de uma preparação para a fabricação de um produto para a prevenção ou o tratamento de ansiedade ou depressão
Sugasini et al. Enrichment of brain docosahexaenoic acid (DHA) is highly dependent upon the molecular carrier of dietary DHA: Lysophosphatidylcholine is more efficient than either phosphatidylcholine or triacylglycerol
DOP2015000026A (es) Formulas de testosterona proliposomal
Yao et al. Effects of vitamin D3‐Enriched diet on egg yolk vitamin D3 content and yolk quality
EA201070419A1 (ru) Состав для регулирования метаболизма липидов
PH12018500036A1 (en) Nutritional compositions containing phosphatidylethanolamine, sphingomyelin and docosahexaenoic acid
Gabbay et al. A double-blind, placebo-controlled trial of omega-3 fatty acids in Tourette’s disorder
RS54100B1 (en) SUBSTANCE USED TO TREAT LIPID METABOLISM DISORDERS
EA201490544A1 (ru) Препараты и лекарственные формы на основе окисленных фосфолипидов
AR105144A1 (es) Composiciones nutricionales y métodos para promover el desarrollo cognitivo
Demirel et al. The metabolic effects of two different lipid emulsions used in parenterally fed premature infants—a randomized comparative study
NZ747847A (en) Lipid compositions
MX2021015311A (es) Formulas parenterales de lisofosfatidilcolina tales como lpc-dha, lpc-epa y sus usos en terapia.
Kotani et al. A naturally occurring rexinoid, honokiol, can serve as a regulator of various retinoid x receptor heterodimers
BR112013027474A2 (pt) composições que melhoram a palatabilidade
BR112014024523A2 (pt) sistema de gordura de panificação
Aster et al. Alterations in membrane fluidity are involved in inhibition of GM-CSF-induced signaling in myeloid cells by zinc
van Wijk et al. Dietary crude lecithin increases systemic availability of dietary docosahexaenoic acid with combined intake in rats
CO6341531A2 (es) Producto alimenticio de acidos grasos con base de chia, rico en omega-3, con buena estabilidad
MX2015007082A (es) Métodos de administración de composiciones que comprenden ácido docosapentanoico.
Chen et al. Lipidomics reveal the cognitive improvement effects of Acer truncatum Bunge seed oil on hypoxic–ischemic encephalopathy rats
MX2014006559A (es) Composicion para el tratamiento o reduccion de sintomas relacionados para el sindrome premestrual (pms), desorden disforico premenstrual (pmdd), premenopausia, menopausia, o desordenes hormonales femeninos en una composicion farmaceutica que contiene dicha forma, y proceso para producir la forma farmaceutica y uso de la composicion.
BR112017019753A2 (pt) uso de composições de astaxantina, composição, processo para preparação de um produto alimentício ou ração, e, preparação medicinal
BR112014029079A2 (pt) composição farmacêutica para administração oral
MX2012007682A (es) Vacuna de aplicacion nasal contra el desarrollo de la enfermedad aterosclerotica y el higado graso.

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements
B350 Update of information on the portal [chapter 15.35 patent gazette]